Develop new therapeutics with unprecedented efficiency by integrating AI systems biology computation with rapid in vivo screening and clinical validation of discovered targets
Unravel Biosciences is the first rapid prototyping therapeutics company leveraging AI models of patient RNA networks for clinical validation and discovery of efficacious theraputics. Unravel is validating a new target for Rett syndrome in the clinic while developing a new small molecule asset, RVL002, that has already demonstrated preclinical efficacy in multiple neurological disorders. Our growing asset pipeline covers CNS and metabolic indications, and we are initiating multiple therapeutics discovery partnerships.
- 1 drug entering clinical POC in Rett syndrome (1 year to pre-IND)
- 200X hit rate of our AI predictions vs. drug screening alone
- 3 weeks to new in vivo disease model & first data
- 3 clinically-validated predictions
- 4 novel targets & mechanisms discovered in months
We can't do this alone.
We are committed to getting patients effective drugs the fastest way possible. We partner with companies, foundations, and researchers to amplify their strengths and datasets through cost-effective decision-making in the areas of target discovery, mechanism identification, drug optimization, and patient stratification for small molecules and biologics.